- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04678323
Pharmacotherapy for Pediatric Obesity: A Phentermine Clinical Trial
Improving Access to Anti-Obesity Pharmacotherapy for Pediatric Obesity: A Randomized Placebo-Controlled Trial of Phentermine
Study Overview
Detailed Description
Obesity in children and adolescents (body mass index [BMI] ≥95th percentile) is a chronic, progressive, and debilitating disease with a prevalence of >20% in the U.S.1 Cardiovascular (CV) complications of obesity in this population are common,2 with nearly 40% of youth having ≥2 CV risk factors. Moreover, obesity in youth increases the risk of CV mortality in adulthood by nearly 5-fold. Treatment of obesity in adolescents includes lifestyle therapy (LST), and when this is ineffective, adjunct pharmacotherapy is recommended.5 However, there are few pharmacological options for pediatric obesity, and none are utilized to any significant degree by primary care pediatricians, even though obesity is the most common chronic disease of childhood.
Currently, orlistat is the only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of obesity in youth ages ≥12 years. However, adoption of orlistat in the clinical setting has been hampered by its significant side effects and poor accessibility due to high cost and poor insurance coverage. Two additional anti-obesity medications, liraglutide and combination phentermine-topiramate, are in the FDA approval pipeline for pediatric obesity, yet these are also unlikely to be widely prescribed by primary care pediatricians. Both of these medications are also expensive and are unlikely to be covered by many insurance plans. Furthermore, liraglutide is delivered by injection and topiramate has associated cognitive side effects. The paucity of safe, effective, and accessible pharmacological options has spurred pediatric obesity specialists to improvise by utilizing medications in an "off-label" manner, resorting to extrapolation of safety and efficacy data from adult clinical trials and opting for medications that are either covered by insurance or are inexpensive. One of the most commonly used medications prescribed in an "off-label" manner is phentermine.
Phentermine, a sympathomimetic, was FDA approved for obesity in 1959, before obesity was considered a chronic disease and when standards for clinical trials were lower than today. Accordingly, it was approved for short-term use, often interpreted as ≤12 weeks, in people ages >16 years. The popularity of phentermine among pediatric obesity specialists is likely driven by its demonstrated safety and efficacy in adults (4-5% mean placebo-subtracted weight loss over 26-28 weeks), oral route of administration, and affordability. Yet in spite of its popularity and routine use beyond 12 weeks, significant gaps exist in our knowledge regarding its safety and efficacy in children and adolescents, many of whom may have abnormal CV profiles at baseline. Indeed, pediatric data regarding phentermine use are sparse: only one retrospective clinical report (published by our group), demonstrated a 4% BMI reduction at 6 months with no significant increase in blood pressure.
To address these important gaps and generate evidence to directly inform clinical care, we propose this multi-site, randomized, placebo-controlled clinical trial to examine the weight loss efficacy and CV safety of phentermine 15 mg daily plus LST vs. placebo plus LST among 200 adolescents ages ≥10 to <18 years with obesity. To maximize the overall impact and clinical scalability, our explicit goal will be to generate the data necessary to support an FDA label change for phentermine to include a pediatric indication (down to age 10 years) and remove restrictions on the duration of use, thereby setting the stage for utilization in the primary care setting.
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male or female, aged 10-<18 years
- BMI ≥ 95th age- and sex-specific Centers for Disease Control (CDC) percentile
- Tanner stage ≥ 1
- Ability to take oral medication and be willing to adhere to the lifestyle therapy regimen
Exclusion Criteria:
- Contraindications to phentermine including: history of cardiovascular disease (including coronary artery disease, stroke, clinically significant congenital heart disease, clinically significant cardiac arrhythmias, congestive heart failure); glaucoma; current or recent (<14 days) use of MAO inhibitors; history of or current chemical dependency; current pregnancy or plans to be pregnant during course of study or lactation; known hypersensitivity to sympathomimetic amines.
- Hypertension
- Cardiac pacemaker
- Type 1 or type 2 diabetes mellitus
- Current or recent (<6 months prior to enrollment) use of weight loss medication(s)
- Current use of other sympathomimetic amines such as ADHD stimulants
- History of bariatric surgery
- Schizophrenia, psychosis, or mania
- Any history of suicide attempt
- Self-harm within 12 months prior to screening
- PHQ-9 score of ≥15 at screening
- Suicidal ideation of type 4 or 5 on C-SSRS in past month
- Hyperthyroidism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Phentermine Plus Lifestyle Therapy
Participants in this arm will receive 15 mg p.o.q.day of phentermine plus lifestyle therapy for 52 weeks.
|
Participants in this group will receive lifestyle management.
|
PLACEBO_COMPARATOR: Placebo Plus Lifestyle Therapy
Participants in this arm will receive a matching placebo plus lifestyle therapy for 52 weeks.
|
Participants in this group will receive lifestyle management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in body mass index (BMI)
Time Frame: 52 weeks
|
To determine the effect of phentermine vs. placebo on body mass index reduction
|
52 weeks
|
Change in systolic and diastolic blood pressure
Time Frame: 52 weeks
|
To determine the effect of phentermine vs. placebo on systolic and diastolic blood pressure
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in triglyceride/HDL ratio
Time Frame: 52 weeks
|
To determine the effect of phentermine vs. placebo on triglyceride and HDL levels in mg/dL
|
52 weeks
|
Change in inflammation
Time Frame: 52 weeks
|
To determine the effect of phentermine vs. placebo on C-reactive protein in mg/L
|
52 weeks
|
Change in oxidative stress
Time Frame: 52 weeks
|
To determine the effect of phentermine vs. placebo on oxidative LDL cholesterol in mg/dL
|
52 weeks
|
Change in Quality of Life
Time Frame: 52 weeks
|
To determine the effect of phentermine vs. placebo on quality of life utilizing the Impact of Weight on Quality of Life-Kids (IWQOL).
This questionnaire has four domains: physical comfort (6 items), body esteem (9 items), social life (6 items) and family relations (6 items).
Scores range from 0 to 100, with 100 representing the best quality of life.
|
52 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPOM-P01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity, Childhood
-
Universiteit LeidenWageningen University; Nutricia, Inc.; Danone ResearchCompletedChildhood Obesity | Childhood Overweight | Vegetable Acceptance in Early ChildhoodNetherlands
-
Vanderbilt University Medical CenterActive, not recruitingPediatric Obesity | Childhood Obesity | Childhood Onset ObesityUnited States
-
Tehran University of Medical SciencesUnknownChildhood Obesity PreventionIran, Islamic Republic of
-
KK Women's and Children's HospitalNot yet recruitingChildhood Obesity PreventionSingapore
-
Cornell UniversityCompletedChildhood Obesity Prevention
-
Oregon State UniversityCompletedChildhood Obesity Prevention
-
The Miriam HospitalHassenfeld Child Health Innovation InstituteCompletedChildhood Obesity PreventionUnited States
-
Fundacion para la Formacion e Investigacion Sanitarias...UnknownChildhood Obesity PreventionSpain
-
Tampere UniversitySeinajoki Central Hospital; Tampere University Hospital; Foundation for Paediatric... and other collaboratorsCompleted
-
Harokopio UniversityCompletedPrevention of Childhood ObesityGreece
Clinical Trials on Lifestyle Management
-
Seoul National University HospitalRecruitingWeight Change, BodyKorea, Republic of
-
Tampere UniversityTampere University Hospital; Sitra, the Finnish Innovation FundCompletedHypertension | Diabetes | Dyslipidemias | Overweight and ObesityFinland
-
UConn HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Penn... and other collaboratorsCompletedDepression | DiabetesUnited States
-
Northwestern UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Osteoarthritis, KneeUnited States
-
University of PittsburghU.S. Air Force Office of the Surgeon GeneralCompleted
-
NYU Langone HealthCompletedCardiovascular DiseaseUnited States
-
Duke UniversityAmerican College of RheumatologyCompletedPain | Obesity | Rheumatoid ArthritisUnited States
-
Norwegian University of Science and TechnologyHelse Nord-Trøndelag HFCompleted
-
Peking University Third HospitalActive, not recruitingObesity | Overweight | PCOSChina
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH); Mount Zion...Completed